Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

N-methyl-D-aspartate receptor antibodies (NMDAR-Abs) can contribute to neurological relapse after herpes simplex virus encephalitis (HSE). We describe a child with NMDAR-Ab encephalitis after HSE, which was recognized and treated early. We discuss the case in the context of existing reports, and we propose a modified immunotherapy strategy to minimize risk of viral reactivation.

Original publication




Journal article


J Pediatric Infect Dis Soc

Publication Date





e17 - e21


HSV, NMDAR, encephalitis, pediatric, plasmapheresis, Acyclovir, Anti-N-Methyl-D-Aspartate Receptor Encephalitis, Antiviral Agents, Autoantibodies, Clonidine, Diazepam, Encephalitis, Herpes Simplex, Encephalomalacia, Female, Fever, Humans, Immunocompromised Host, Immunosuppression, Infant, Leukoencephalopathies, Movement Disorders, Neurological Rehabilitation, Pakistan, Paresis, Phenobarbital, Phenytoin, Plasmapheresis, Receptors, N-Methyl-D-Aspartate, Seizures, Trihexyphenidyl, United Kingdom, Valproic Acid